1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Global Markets for Vaccine Technologies

Global Markets for Vaccine Technologies

  • January 2017
  • -
  • BCC Research
  • -
  • 184 pages

Use this report to:
- Identify the areas of market growth among vaccine manufacturers and users.
- Gain insight into the regulatory aspects, current and developing technologies, market projections and market share with respect to vaccine technologies.
- Receive information on the acquisition strategies and collaborations by companies along with the strengths and weaknesses of each strategy type.
- Evaluate the market size for human and animal vaccines.

Highlights
- The global market for vaccine technologies reached $33.3 billion in 2016 and should reach $45.2 billion by 2021, growing at a compound annual growth rate (CAGR) of 6.3% from 2016 to 2021.
- Human vaccines as a segment of this market reached $27.2 billion in 2016 and should reach nearly $37.5 billion by 2021, growing at a CAGR of 6.6% from 2016 to 2021.
- Animal vaccines as a segment of this market reached nearly $6.1 billion in 2016 and should reach $7.7 billion by 2021, growing at a CAGR of 4.9% from 2016 to 2021.

STUDY OBJECTIVES
Vaccines are an important part of the global healthcare market. Human vaccines are available for a wide range of diseases such as polio; measles, mumps and rubella (MMR); tetanus; diphtheria; hepatitis and influenza. Animal health vaccines offer applications such as antibiotics, parasiticides and medicinal feed additives and vaccines for both livestock and companion animals. BCC Research’s goal in conducting this study is to provide an overview of the current and future characteristics of the global market for vaccine technology.

This report explores present and future strategies within the vaccine technology market, which is divided into vaccines for both humans and animals. The outlook of the market, the setbacks and the needs of the market are discussed in this report. The classifications and usage of these products are also described in this report.

A detailed analysis of the vaccine technology industry’s structure has been conducted. The revenues are broken down by region, while sales figures are estimated for the five-year period from 2016 through 2021. The applications of these vaccines are discussed separately in the report. The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THIS STUDY
Vaccines are one of the most cost-effective ways to reduce the global disease load. The global rise in infectious and noninfectious diseases, the growing population, advancements in science and technology, as well as the resurgence of vaccine preventable diseases and the emergence of new pandemics and immunization programs run in developing geographies are influencing the global vaccines market.

In humans, vaccines are used to prevent or treat various human diseases. Based on whether they prevent diseases or treat pre-existing ones, vaccines can be divided broadly into prophylactic and therapeutic vaccines. In contrast, animal vaccines are categorized for food-producing animals (porcine, bovine, poultry, ovine, fish) and for companion animals (canine, feline and equine vaccines) and other animal vaccines (rabbit, etc.).

Research and development (R&D spending, along with increasing competition and new technologies are giving direction to the market. These advancements, new product launches and changing lifestyles are influencing future market growth. This study looks at almost all the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. In addition, this study also discusses the strengths and weaknesses of each strategy type in light of the new technologies, growing competition and changing customer needs.

The market also has been analyzed based on the application of these vaccines. Categories considered in this report are meningococcal/pneumococcal vaccines, influenza vaccines, pediatric polio/pertussis/Hib vaccines, adult/adolescent booster vaccines, vaccines for travel-related and other endemic diseases, HPV vaccines, rotavirus vaccines and other (minor) vaccines.

CONTRIBUTIONS OF THE STUDY AND FOR WHOM
This study contributes to the areas of market growth among vaccine manufacturers and users. Genomic research centers, academic institutions, government and private laboratories, various hospital settings as well as pharmaceutical, diagnostic and biotechnology companies and physicians will find this study to be of interest.

SCOPE OF THE STUDY
The scope of this study entails the current market for human and animal vaccines. The report also includes regulatory aspects, current and developing technologies, market projections and market share. An analysis of patents, clinical trials, innovations and opportunities, as well as the latest trends is also discussed. Sales data for the global and regional markets were corroborated for the present and forecasted values based on statistical analysis. Regions are categorized into the United States, Europe and the emerging markets, which include India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand. The application of vaccines in various diseases is discussed from both a commercial and R&D perspective.

METHODOLOGY
Both primary and secondary research methodologies were used in preparing this study. BCC Research conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with manufacturers and users of vaccine technology products. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

INFORMATION SOURCES
Many companies were surveyed to obtain data for this study. Included were manufacturers and end users of vaccine technology. Data were gathered from various industry sources. In addition, BCC Research interviewed industry officials, consulted newsletters, company literature, product literature and various technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.

ANALYSTS’ CREDENTIALS
The study has been carried out by a team of professionals in the biotechnology industry. The project manager is Shalini S. Dewan, who holds a master’s degree in pharmaceutical chemistry and has more than 17 years of industry experience. She was awarded a Gold Medal by the prime minister of India for her work and has worked with top companies in India and in the United States.

Table Of Contents

Global Markets for Vaccine Technologies
CHAPTER 1
INTRODUCTION 2
STUDY OBJECTIVES 2
REASONS FOR DOING THIS STUDY 2
CONTRIBUTIONS OF THE STUDY AND FOR WHOM 3
SCOPE OF THE STUDY 3
METHODOLOGY 3
INFORMATION SOURCES 3
ANALYSTS' CREDENTIALS 3
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH WEBSITE 4
DISCLAIMER 5
CHAPTER 2 EXECUTIVE SUMMARY 7
SUMMARY TABLE GLOBAL MARKET FOR VACCINE TECHNOLOGIES, BY SEGMENT, THROUGH 2021 ($ MILLIONS) 8
SUMMARY FIGURE GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, 2014-2021 ($ MILLIONS) 8
CHAPTER 3 OVERVIEW 10
DEFINITIONS 10
THE IMMUNE SYSTEM 11
HOW VACCINES WORK 11
TYPES OF IMMUNITY 12
ACTIVE 12
PASSIVE 12
ADVANTAGES OF VACCINATION 12
HISTORY OF VACCINES 13
TABLE 1 HISTORY OF VACCINES 13
TYPES OF VACCINES 15
ATTENUATED (LIVE) VACCINES 15
Types of Attenuated (Live) Vaccines 15
TABLE 2 TYPES OF ATTENUATED (LIVE) VACCINES 16
Advantages and Disadvantages of Attenuated (Live) Vaccines 17
TABLE 3 ADVANTAGES AND DISADVANTAGES OF ATTENUATED (LIVE) VACCINES 17
INACTIVATED (KILLED) VACCINES 17
Types of Inactivated (Killed) Vaccines 18
TABLE 4 TYPES OF INACTIVATED (KILLED) VACCINES 18
Advantages and Disadvantages of Inactivated (Killed) Vaccines 18
TABLE 5 ADVANTAGES AND DISADVANTAGES OF INACTIVATED (KILLED) VACCINES 19
TOXOID VACCINES 19
Types of Toxoid Vaccines 19
TABLE 6 TYPES OF TOXOID VACCINES 20
Advantages and Disadvantages of Toxoid Vaccines 20
TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES 20
SUBUNIT VACCINES 21
Types of Subunit Vaccines 21
TABLE 8 TYPES OF SUBUNIT VACCINES 21
Advantages and Disadvantages of Subunit Vaccines 22
TABLE 9 ADVANTAGES AND DISADVANTAGES OF SUBUNIT VACCINES 22
CONJUGATE VACCINES 22
Types of Conjugate Vaccines 23
TABLE 10 TYPES OF CONJUGATE VACCINES 23
Advantages and Disadvantages of Conjugate Vaccines 23
TABLE 11 ADVANTAGES AND DISADVANTAGES OF CONJUGATE VACCINES 23
RECOMBINANT VECTOR VACCINES 23
Types of Recombinant Vector Vaccines 24
TABLE 12 TYPES OF RECOMBINANT VECTOR VACCINES 24
Advantages and Disadvantages of Recombinant Vector Vaccines 24
TABLE 13 ADVANTAGES AND DISADVANTAGES OF RECOMBINANT VECTOR
VACCINES 25
DNA VACCINES 25
Types of DNA Vaccines 25
TABLE 14 TYPES OF DNA VACCINES 26
Advantages and Disadvantages of DNA vaccines 26
TABLE 15 ADVANTAGES AND DISADVANTAGES OF DNA VACCINES 26
INFECTIOUS DISEASES PREVENTABLE BY VACCINES 27
HUMAN DISEASES 27
Viral Diseases 27
TABLE 16 VACCINE-PREVENTABLE HUMAN VIRAL DISEASES 28
Bacterial Diseases 30
TABLE 17 VACCINE-PREVENTABLE HUMAN BACTERIAL DISEASES 30
ANIMAL DISEASES 33
Food-Producing Animals 34
TABLE 18 VACCINE-PREVENTABLE PARASITIC ANIMAL DISEASES FOUND IN FOOD-PRODUCING ANIMALS 34
TABLE 19 VACCINE-PREVENTABLE BACTERIAL ANIMAL DISEASES FOUND IN FOOD-PRODUCING ANIMALS 35
TABLE 20 VACCINE-PREVENTABLE VIRAL ANIMAL DISEASES FOUND IN FOOD-PRODUCING ANIMALS 36
Companion Animals 37
TABLE 21 VACCINE-PREVENTABLE PARASITIC ANIMAL DISEASES FOUND IN COMPANION ANIMALS 37
TABLE 22 VACCINE-PREVENTABLE BACTERIAL ANIMAL DISEASES FOUND IN COMPANION ANIMALS 37
TABLE 23 VACCINE-PREVENTABLE VIRAL ANIMAL DISEASES FOUND IN COMPANION ANIMALS 38
Other Animals 38
TABLE 24 VACCINE-PREVENTABLE VIRAL ANIMAL DISEASES FOUND IN OTHER ANIMALS 39
TABLE 25 ANIMAL VACCINES FOR FOOD-PRODUCING, COMPANION AND OTHER ANIMALS 40
CHAPTER 4 REGULATORY ASPECTS 46
REGULATORY ASPECTS 46
WORLD HEALTH ORGANIZATION (WHO) PREQUALIFIED VACCINES 46
TABLE 26 WHO PREQUALIFIED VACCINES, JANUARY 2014-SEPTEMBER 2016 46
NEW PRODUCT APPROVALS 51
TABLE 27 NEWLY APPROVED VACCINES, 2014-SEPTEMBER 2016 51
RECALLS 51
TABLE 28 GLOBAL VACCINE RECALLS, JANUARY 2014-SEPTEMBER 2016 52
VACCINE SHORTAGE 52
TABLE 29 GLOBAL VACCINE SHORTAGE, JANUARY 2012-SEPTEMBER 2016 52
SIGNIFICANT REGULATORY DEVELOPMENTS IN VACCINE-PREVENTABLE DISEASE PRODUCTS 52
CHAPTER 5 NEW DEVELOPMENTS 55
TABLE 30 HUMAN VACCINES IN THE RESEARCH PIPELINE AS OF SEPTEMBER 2016 55
ALLIANCES AND JOINT VENTURES 57
TABLE 31 ALLIANCES AND JOINT VENTURES FOR THE DEVELOPMENT OF HUMAN AND ANIMAL VACCINES, JANUARY 2014-SEPTEMBER 2016 58
NEW PRODUCT LAUNCHES 59
TABLE 32 NEWLY VACCINES LAUNCHED, JANUARY 2014-SEPTEMBER 2016 60
CHAPTER 6 MARKET ANALYSIS OF HUMAN VACCINES 62
MARKET BY TYPE 63
MARKET OVERVIEW 63
MARKET REVENUE 64
TABLE 33 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, THROUGH 2021 ($ MILLIONS) 64
FIGURE 1 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, 2014-2021 ($ MILLIONS) 64
MARKET SHARE 65
TABLE 34 GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2015 (%) 65
FIGURE 2 GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2015 (%) 66
MARKET BY REGION 66
MARKET OVERVIEW 66
MARKET REVENUE 67
TABLE 35 GLOBAL SALES OF HUMAN VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 68
FIGURE 3 GLOBAL SALES OF HUMAN VACCINES BY REGION, 2014-2021 ($ MILLIONS) 68
MARKET SHARE 68
TABLE 36 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2015 (%) 69
FIGURE 4 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2015 (%) 69
REGIONAL MARKETS FOR ATTENUATED (LIVE) VACCINES 69
Market Overview 70
Market Revenue 70
TABLE 37 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINE, BY REGION, THROUGH 2021 ($ MILLIONS) 71
FIGURE 5 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINE BY REGION, 2014-2021 ($ MILLIONS) 72
REGIONAL MARKETS FOR INACTIVATED VACCINES 72
Market Overview 72
Market Revenue 73
TABLE 38 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES, BY REGION, THROUGH 2021 ($ MILLIONS) 74
FIGURE 6 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES BY REGION, 2014-2021 ($ MILLIONS) 74
REGIONAL MARKETS FOR CONJUGATE VACCINES 74
Market Overview 75
Market Revenue 76
TABLE 39 GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 77
FIGURE 7 GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION, 2014-2021 ($ MILLIONS) 77
REGIONAL MARKETS FOR RDNA/ DNA VACCINES 77
Market Overview 78
Market Revenue 78
TABLE 40 GLOBAL MARKET FOR RECOMBINANT/RDNA/DNA VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 79
FIGURE 4 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2015 (%) 79
REGIONAL MARKETS FOR SUBUNIT VACCINES 80
Market Overview 80
Market Revenue 80
TABLE 41 GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 81
FIGURE 9 GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION, 2014-2021 ($ MILLIONS) 81
REGIONAL MARKETS FOR TOXOID VACCINES 82
Market Overview 82
Market Revenue 82
TABLE 42 GLOBAL MARKET FOR TOXOID VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 83
FIGURE 10 GLOBAL MARKET FOR TOXOID VACCINES BY REGION, 2014-2021 ($ MILLIONS) 83
REGIONAL MARKETS FOR OTHER/COMBINATION VACCINES 83
Market Overview 83
Market Revenue 84
TABLE 43 GLOBAL MARKET FOR OTHER/COMBINATION VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 84
FIGURE 11 GLOBAL MARKET FOR OTHER/COMBINATION VACCINES BY REGION, 2014-2021 ($ MILLIONS) 85
CHAPTER 7 MARKET ANALYSIS OF ANIMAL VACCINES 87
MARKET OVERVIEW 87
MARKET REVENUE 88
TABLE 44 GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET LEADER, 2014-2016 ($ MILLIONS) 89
FIGURE 12 GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET LEADER, 2014-2016 ($ MILLIONS) 89
ANIMAL VACCINES 90
MARKET BY TYPE 92
TABLE 45 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, THROUGH 2021 ($ MILLIONS) 92
FIGURE 13 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, 2014-2021 ($ MILLIONS) 92
VACCINES USED IN FOOD-PRODUCING ANIMALS 93
Market Overview 93
Market Revenue 96
TABLE 46 GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING ANIMALS BY REGION, THROUGH 2021 ($ MILLIONS) 96
FIGURE 14 GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING ANIMALS BY REGION, 2014-2021 ($ MILLIONS) 97
COMPANION ANIMAL VACCINES 97
Market Overview 97
Market Revenue 98
TABLE 47 GLOBAL MARKET FOR VACCINES FOR COMPANION ANIMALS BY REGION, THROUGH 2021 ($ MILLIONS) 99
FIGURE 15 GLOBAL MARKET FOR VACCINES FOR COMPANION ANIMALS BY REGION, 2014-2021 ($ MILLIONS) 99
OTHER ANIMAL VACCINES 99
Market Overview 100
Market Revenue 100
TABLE 48 GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 101
FIGURE 16 GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY REGION, 2014-2021 ($ MILLIONS) 101
MARKET SHARE 101
TABLE 49 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2015 (%) 102
FIGURE 17 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2015 (%) 102
MARKET BY REGION 102
MARKET OVERVIEW 103
MARKET REVENUE 103
TABLE 50 GLOBAL SALES OF ANIMAL VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 104
FIGURE 18 GLOBAL SALES OF ANIMAL VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 104
MARKET SHARE 104
TABLE 51 GLOBAL MARKET SHARES OF ANIMAL VACCINE SALES BY REGION, 2015 (%) 105
FIGURE 19 GLOBAL MARKET SHARES OF ANIMAL VACCINE SALES BY REGION, 2015 (%) 105
CHAPTER 8 INDUSTRY STRUCTURE 107
MARKET LEADERS IN HUMAN VACCINE 107
TABLE 52 LEADING MANUFACTURERS/ SUPPLIERS OF HUMAN VACCINES 107
MARKET SHARE OF HUMAN VACCINE 113
TABLE 53 GLOBAL MARKET SHARE OF MANUFACTURERS OF HUMAN VACCINE, 2015 (%) 113
FIGURE 20 GLOBAL MARKET SHARE OF MANUFACTURERS OF HUMAN VACCINE, 2015 (%) 114
MARKET LEADERS IN ANIMAL VACCINE 114
TABLE 54 LEADING MANUFACTURERS/SUPPLIERS OF ANIMAL VACCINES 115
MARKET SHARE OF ANIMAL VACCINE 117
TABLE 55 ANIMAL VACCINE MANUFACTURERS' GLOBAL MARKET SHARE, 2015 (%) 118
FIGURE 21 ANIMAL VACCINE MANUFACTURERS GLOBAL MARKET SHARE, 2015 (%) 118
CHAPTER 9 MARKET BY APPLICATION FOR HUMAN VACCINES 120
PROPHYLACTIC VACCINES 120
THERAPEUTIC VACCINES 120
TABLE 56 HUMAN VACCINES BASED ON MICROORGANISM 121
MENINGOCOCCAL/PNEUMOCOCCAL DISEASES 122
MENINGOCOCCAL 122
PNEUMOCOCCAL DISEASES 123
MARKET REVENUE 123
TABLE 57 GLOBAL SALES OF HUMAN VACCINES FOR MENINGOCOCCAL/ PNEUMOCOCCAL DISEASES, THROUGH 2021 ($ MILLIONS) 124
FIGURE 22 GLOBAL SALES OF HUMAN VACCINES FOR MENINGOCOCCAL/ PNEUMOCOCCAL DISEASES, 2014-2021 ($ MILLIONS) 124
MARKET SHARE 124
TABLE 58 GLOBAL MARKET SHARES OF TOP-SELLING MENINGOCOCCAL/ PNEUMOCOCCAL VACCINES, 2015 (%) 125
FIGURE 23 GLOBAL MARKET SHARES OF TOP-SELLING MENINGOCOCCAL/ PNEUMOCOCCAL VACCINES, 2015 (%) 125
INFLUENZA (SEASONAL AND PANDEMIC DISEASE) 125
MARKET REVENUE 126
TABLE 59 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET, THROUGH 2021 ($ MILLIONS) 127
FIGURE 24 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET, 2014-2021 ($ MILLIONS) 127
MARKET SHARE 127
TABLE 60 GLOBAL MARKET SHARES OF TOP-SELLING INFLUENZA VACCINES, 2015 (%) 128
FIGURE 25 GLOBAL MARKET SHARES OF TOP-SELLING INFLUENZA VACCINES, 2015 (%) 128
PEDIATRIC POLIO/PERTUSSIS/HIB 129
MARKET REVENUE 130
TABLE 61 GLOBAL MARKET FOR HUMAN VACCINES PEDIATRIC POLIO/PERTUSSIS/HIB DISEASES, THROUGH 2021 ($ MILLIONS) 131
FIGURE 26 GLOBAL MARKET FOR HUMAN VACCINES PEDIATRIC POLIO/PERTUSSIS/HIB DISEASES MARKET, 2014-2021 ($ MILLIONS) 131
MARKET SHARE 131
TABLE 62 GLOBAL MARKET SHARES OF TOP-SELLING PEDIATRIC POLIO/PERTUSSIS/HIB VACCINES, 2015 (%) 131
FIGURE 27 GLOBAL MARKET SHARES OF TOP-SELLING PEDIATRIC POLIO/PERTUSSIS/HIB VACCINES, 2015 (%) 132
ADULT/ADOLESCENT BOOSTER VACCINES 132
MARKET REVENUE 133
TABLE 63 GLOBAL MARKET FOR HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER DISEASES, THROUGH 2021 ($ MILLIONS) 133
FIGURE 28 GLOBAL MARKET FOR HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER DISEASES, 2014-2021 ($ MILLIONS) 134
MARKET SHARE 134
TABLE 64 GLOBAL MARKET SHARES OF TOP-SELLING ADULT/ADOLESCENT BOOSTER VACCINES, 2015 (%) 134
FIGURE 29 GLOBAL MARKET SHARES OF TOP-SELLING ADULT/ADOLESCENT BOOSTER VACCINES, 2015 (%) 134
TRAVEL-RELATED AND OTHER ENDEMIC DISEASES 135
MARKET REVENUE 136
TABLE 65 GLOBAL MARKET FOR HUMAN VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, THROUGH 2021 ($ MILLIONS) 137
FIGURE 30 GLOBAL MARKET FOR HUMAN VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, 2014-2021 ($ MILLIONS) 137
MARKET SHARE 137
TABLE 66 GLOBAL MARKET SHARES OF TOP-SELLING VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, 2015 (%) 138
FIGURE 31 GLOBAL MARKET SHARES OF TOP-SELLING VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, 2015 (%) 138
HPV DISEASE 138
MARKET REVENUE 140
TABLE 67 GLOBAL MARKET FOR HUMAN VACCINES IN HPV, THROUGH 2021 ($ MILLIONS) 140
FIGURE 32 GLOBAL MARKET FOR HUMAN VACCINES IN HPV, 2014-2021 ($ MILLIONS) 140
MARKET SHARE 141
TABLE 68 GLOBAL MARKET SHARES OF TOP-SELLING HPV VACCINES, 2015 (%) 141
FIGURE 33 GLOBAL MARKET SHARES OF TOP-SELLING HPV VACCINES, 2015 (%) 141
ROTAVIRUS DISEASE 142
MARKET REVENUE 143
TABLE 69 GLOBAL MARKET FOR HUMAN VACCINES IN ROTAVIRUS, THROUGH 2021 ($ MILLIONS) 143
FIGURE 34 GLOBAL MARKET FOR HUMAN VACCINES IN ROTAVIRUS, 2014-2021 ($ MILLIONS) 143
MARKET SHARE 144
TABLE 70 GLOBAL MARKET SHARES OF TOP-SELLING ROTAVIRUS VACCINES, 2015 (%) 144
FIGURE 35 GLOBAL MARKET SHARES OF TOP-SELLING ROTAVIRUS VACCINES, 2015 (%) 144
OTHER DISEASES 144
MARKET REVENUE 145
TABLE 71 GLOBAL MARKET FOR HUMAN VACCINES IN THE OTHER DISEASES SEGMENT, THROUGH 2021 ($ MILLIONS) 146
FIGURE 36 GLOBAL MARKET FOR HUMAN VACCINES IN THE OTHER DISEASES SEGMENT, 2014-2021 ($ MILLIONS) 146
MARKET SHARE 147
TABLE 72 GLOBAL MARKET SHARES OF TOP-SELLING VACCINES IN THE OTHER DISEASES SEGMENT, 2015 (%) 147
FIGURE 37 GLOBAL MARKET SHARES OF TOP-SELLING VACCINES IN THE OTHER DISEASES SEGMENT, 2015 (%) 147
MARKET SHARE OF APPLICATIONS 148
TABLE 73 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION, 2015 (%) 148
FIGURE 38 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION, 2015 (%) 149
CHAPTER 10 PATENT ANALYSIS 151
PATENTS BY YEAR 151
TABLE 74 U.S. PATENTS ISSUED FOR VACCINES BY YEAR, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS) 151
FIGURE 39 U.S. PATENTS ISSUED FOR VACCINES BY YEAR, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS) 152
PATENTS BY VACCINE TYPE 152
TABLE 75 U.S. PATENTS BY TYPE OF VACCINES, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS) 152
FIGURE 40 U.S. PATENTS BY TYPE OF VACCINES, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS) 153
PATENTS BY ASSIGNEE'S COUNTRY 153
TABLE 76 U.S. PATENTS BY ASSIGNEE'S COUNTRY, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS) 153
TABLE 77 GLOBAL PATENT SHARES BY PATENT HOLDER'S COUNTRY, JANUARY 2014-SEPTEMBER 2016 (%) 154
FIGURE 41 PATENT SHARES BY PATENT HOLDER'S COUNTRY, JANUARY 2014-SEPTEMBER 2016 (%) 155
PATENTS BY COMPANY 156
TABLE 78 U.S. PATENTS BY COMPANY, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS) 156
PATENTS BY ASSIGNEE 157
TABLE 79 U.S. PATENTS BY ASSIGNEE TYPE, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS) 157
FIGURE 42 U.S. PATENTS BY ASSIGNEE TYPE, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS) 157
CHAPTER 11 CURRENT SITUATION 160
HUMAN VACCINES 160
DEVELOPMENT AND LAUNCH OF NEW VACCINES 161
INCREASED RandD EFFORTS 161
INCREASED DEMAND FROM EMERGING MARKETS 161
GOVERNMENT INITIATIVES FOR INCREASED IMMUNIZATIONS 161
HIGH PRICES OF VACCINES 162
PRICING PRESSURE 162
GLOBAL ALLIANCE FOR VACCINES AND IMMUNIZATION (GAVI) 162
RISING CONCERNS OF ASSOCIATED RISK FACTORS 163
INADEQUATE VACCINE SUPPLY 164
COLLABORATIONS, LICENSING AGREEMENTS, MERGERS AND ACQUISITIONS 164
ANIMAL VACCINES 165
CHAPTER 12 COMPANY PROFILES 167
ABBOTT LABORATORIES 167
AERAS GLOBAL 167
ASTELLAS PHARMA INC. 168
ASTRAZENECA PLC 168
BAXTER INTERNATIONAL INC. 169
BAYER ANIMAL HEALTH 170
BHARAT BIOTECH INTERNATIONAL LIMITED 170
BIOLOGICAL E. LTD. 171
BIO-MANGUINHOS 172
BIOPROPERTIES PTY LTD. 172
BOEHRINGER INGELHEIM GMBH 173
BUL BIO - NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES LTD. (BB-NCIPD LTD.) 174
CADILA HEALTHCARE LTD. (ZYDUS CADILA) 174
CEVA SANTE ANIMALE 175
CHINA NATIONAL BIOTEC GROUP (CNBG) 175
COLORADO SERUM COMPANY 176
CSL LIMITED 176
ELANCO ANIMAL HEALTH 177
EMERGENT BIOSOLUTIONS INC. 178
FATRO S.P.A. 179
GENVEC INC. 179
GENEONE LIFE SCIENCES INC 180
GEOVAX 180
GLAXOSMITHKLINE PLC 181
GREEN CROSS CORP 182
INSTITUT PASTEUR DE DAKAR 182
JAPAN BCG LABORATORY 183
LG LIFE SCIENCES 183
JOHNSON AND JOHNSON INC 184
MERCK and CO. INC. 184
MERIAL S.A.S. 185
NOVARTIS PHARMA AG 186
PANACEA BIOTEC LTD. 187
PFENEX INC. 187
PFIZER INC. 188
PROFECTUS BIOSCIENCES INC. 188
PT BIO FARMA 189
SANOFI PASTEUR 189
SERUM INSTITUTE OF INDIA LIMITED 190
STATENS SERUM INSTITUT 191
VALNEVA SE 191
VIRBAC 192
ZOETIS INC. 192
CHAPTER 13 APPENDIX I - ABBREVIATIONS 195

LIST OF TABLES
SUMMARY TABLE GLOBAL MARKET FOR VACCINE TECHNOLOGIES, BY SEGMENT, THROUGH 2021 ($ MILLIONS) 8
TABLE 1 HISTORY OF VACCINES 13
TABLE 2 TYPES OF ATTENUATED (LIVE) VACCINES 16
TABLE 3 ADVANTAGES AND DISADVANTAGES OF ATTENUATED (LIVE) VACCINES 17
TABLE 4 TYPES OF INACTIVATED (KILLED) VACCINES 18
TABLE 5 ADVANTAGES AND DISADVANTAGES OF INACTIVATED (KILLED) VACCINES 19
TABLE 6 TYPES OF TOXOID VACCINES 20
TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES 20
TABLE 8 TYPES OF SUBUNIT VACCINES 21
TABLE 9 ADVANTAGES AND DISADVANTAGES OF SUBUNIT VACCINES 22
TABLE 10 TYPES OF CONJUGATE VACCINES 23
TABLE 11 ADVANTAGES AND DISADVANTAGES OF CONJUGATE VACCINES 23
TABLE 12 TYPES OF RECOMBINANT VECTOR VACCINES 24
TABLE 13 ADVANTAGES AND DISADVANTAGES OF RECOMBINANT VECTOR VACCINES 25
TABLE 14 TYPES OF DNA VACCINES 26
TABLE 15 ADVANTAGES AND DISADVANTAGES OF DNA VACCINES 26
TABLE 16 VACCINE-PREVEN
TABLE HUMAN VIRAL DISEASES 28
TABLE 17 VACCINE-PREVEN
TABLE HUMAN BACTERIAL DISEASES 30
TABLE 18 VACCINE-PREVEN
TABLE PARASITIC ANIMAL DISEASES FOUND IN FOOD-PRODUCING ANIMALS 34
TABLE 19 VACCINE-PREVEN
TABLE BACTERIAL ANIMAL DISEASES FOUND IN FOOD-PRODUCING ANIMALS 35
TABLE 20 VACCINE-PREVEN
TABLE VIRAL ANIMAL DISEASES FOUND IN FOOD-PRODUCING ANIMALS 36
TABLE 21 VACCINE-PREVEN
TABLE PARASITIC ANIMAL DISEASES FOUND IN COMPANION ANIMALS 37
TABLE 22 VACCINE-PREVEN
TABLE BACTERIAL ANIMAL DISEASES FOUND IN COMPANION ANIMALS 37
TABLE 23 VACCINE-PREVEN
TABLE VIRAL ANIMAL DISEASES FOUND IN COMPANION ANIMALS 38
TABLE 24 VACCINE-PREVEN
TABLE VIRAL ANIMAL DISEASES FOUND IN OTHER ANIMALS 39
TABLE 25 ANIMAL VACCINES FOR FOOD-PRODUCING, COMPANION AND OTHER ANIMALS 40
TABLE 26 WHO PREQUALIFIED VACCINES, JANUARY 2014-SEPTEMBER 2016 46
TABLE 27 NEWLY APPROVED VACCINES, 2014-SEPTEMBER 2016 51
TABLE 28 GLOBAL VACCINE RECALLS, JANUARY 2014-SEPTEMBER 2016 52
TABLE 29 GLOBAL VACCINE SHORTAGE, JANUARY 2012-SEPTEMBER 2016 52
TABLE 30 HUMAN VACCINES IN THE RESEARCH PIPELINE AS OF SEPTEMBER 2016 55
TABLE 31 ALLIANCES AND JOINT VENTURES FOR THE DEVELOPMENT OF HUMAN AND ANIMAL VACCINES, JANUARY 2014-SEPTEMBER 2016 58
TABLE 32 NEWLY VACCINES LAUNCHED, JANUARY 2014-SEPTEMBER 2016 60
TABLE 33 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, THROUGH 2021 ($ MILLIONS) 64
TABLE 34 GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2015 (%) 65
TABLE 35 GLOBAL SALES OF HUMAN VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 68
TABLE 36 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2015 (%) 69
TABLE 37 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINE, BY REGION, THROUGH 2021 ($ MILLIONS) 71
TABLE 38 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES, BY REGION, THROUGH 2021 ($ MILLIONS) 74
TABLE 39 GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 77
TABLE 40 GLOBAL MARKET FOR RECOMBINANT/RDNA/DNA VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 79
TABLE 41 GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 81
TABLE 42 GLOBAL MARKET FOR TOXOID VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 83
TABLE 43 GLOBAL MARKET FOR OTHER/COMBINATION VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 84
TABLE 44 GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET LEADER, 2014-2016 ($ MILLIONS) 89
TABLE 45 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, THROUGH 2021 ($ MILLIONS) 92
TABLE 46 GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING ANIMALS BY REGION, THROUGH 2021 ($ MILLIONS) 96
TABLE 47 GLOBAL MARKET FOR VACCINES FOR COMPANION ANIMALS BY REGION, THROUGH 2021 ($ MILLIONS) 99
TABLE 48 GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 101
TABLE 49 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2015 (%) 102
TABLE 50 GLOBAL SALES OF ANIMAL VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 104
TABLE 51 GLOBAL MARKET SHARES OF ANIMAL VACCINE SALES BY REGION, 2015 (%) 105
TABLE 52 LEADING MANUFACTURERS/ SUPPLIERS OF HUMAN VACCINES 107
TABLE 53 GLOBAL MARKET SHARE OF MANUFACTURERS OF HUMAN VACCINE, 2015 (%) 113
TABLE 54 LEADING MANUFACTURERS/SUPPLIERS OF ANIMAL VACCINES 115
TABLE 55 ANIMAL VACCINE MANUFACTURERS' GLOBAL MARKET SHARE, 2015 (%) 118
TABLE 56 HUMAN VACCINES BASED ON MICROORGANISM 121
TABLE 57 GLOBAL SALES OF HUMAN VACCINES FOR MENINGOCOCCAL/ PNEUMOCOCCAL DISEASES, THROUGH 2021 ($ MILLIONS) 124
TABLE 58 GLOBAL MARKET SHARES OF TOP-SELLING MENINGOCOCCAL/ PNEUMOCOCCAL VACCINES, 2015 (%) 125
TABLE 59 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET, THROUGH 2021 ($ MILLIONS) 127
TABLE 60 GLOBAL MARKET SHARES OF TOP-SELLING INFLUENZA VACCINES, 2015 (%) 128
TABLE 61 GLOBAL MARKET FOR HUMAN VACCINES PEDIATRIC POLIO/PERTUSSIS/HIB DISEASES, THROUGH 2021 ($ MILLIONS) 131
TABLE 62 GLOBAL MARKET SHARES OF TOP-SELLING PEDIATRIC POLIO/PERTUSSIS/HIB VACCINES, 2015 (%) 131
TABLE 63 GLOBAL MARKET FOR HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER DISEASES, THROUGH 2021 ($ MILLIONS) 133
TABLE 64 GLOBAL MARKET SHARES OF TOP-SELLING ADULT/ADOLESCENT BOOSTER VACCINES, 2015 (%) 134
TABLE 65 GLOBAL MARKET FOR HUMAN VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, THROUGH 2021 ($ MILLIONS) 137
TABLE 66 GLOBAL MARKET SHARES OF TOP-SELLING VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, 2015 (%) 138
TABLE 67 GLOBAL MARKET FOR HUMAN VACCINES IN HPV, THROUGH 2021 ($ MILLIONS) 140
TABLE 68 GLOBAL MARKET SHARES OF TOP-SELLING HPV VACCINES, 2015 (%) 141
TABLE 69 GLOBAL MARKET FOR HUMAN VACCINES IN ROTAVIRUS, THROUGH 2021 ($ MILLIONS) 143
TABLE 70 GLOBAL MARKET SHARES OF TOP-SELLING ROTAVIRUS VACCINES, 2015 (%) 144
TABLE 71 GLOBAL MARKET FOR HUMAN VACCINES IN THE OTHER DISEASES SEGMENT, THROUGH 2021 ($ MILLIONS) 146
TABLE 72 GLOBAL MARKET SHARES OF TOP-SELLING VACCINES IN THE OTHER DISEASES SEGMENT, 2015 (%) 147
TABLE 73 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION, 2015 (%) 148
TABLE 74 U.S. PATENTS ISSUED FOR VACCINES BY YEAR, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS) 151
TABLE 75 U.S. PATENTS BY TYPE OF VACCINES, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS) 152
TABLE 76 U.S. PATENTS BY ASSIGNEE'S COUNTRY, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS) 153
TABLE 77 GLOBAL PATENT SHARES BY PATENT HOLDER'S COUNTRY, JANUARY 2014-SEPTEMBER 2016 (%) 154
TABLE 78 U.S. PATENTS BY COMPANY, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS) 156
TABLE 79 U.S. PATENTS BY ASSIGNEE TYPE, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS) 157


LIST OF FIGURES
SUMMARY FIGURE GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, 2014-2021 ($ MILLIONS) 8
FIGURE 1 GLOBAL MARKET FOR HUMAN VACCINES BY TYPE, 2014-2021 ($ MILLIONS) 64
FIGURE 2 GLOBAL MARKET SHARES OF SALES OF HUMAN VACCINES BY TYPE, 2015 (%) 66
FIGURE 3 GLOBAL SALES OF HUMAN VACCINES BY REGION, 2014-2021 ($ MILLIONS) 68
FIGURE 4 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2015 (%) 69
FIGURE 5 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINE BY REGION, 2014-2021 ($ MILLIONS) 72
FIGURE 6 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES BY REGION, 2014-2021 ($ MILLIONS) 74
FIGURE 7 GLOBAL MARKET FOR CONJUGATE VACCINES BY REGION, 2014-2021 ($ MILLIONS) 77
FIGURE 4 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY REGION, 2015 (%) 79
FIGURE 9 GLOBAL MARKET FOR SUBUNIT VACCINES BY REGION, 2014-2021 ($ MILLIONS) 81
FIGURE 10 GLOBAL MARKET FOR TOXOID VACCINES BY REGION, 2014-2021 ($ MILLIONS) 83
FIGURE 11 GLOBAL MARKET FOR OTHER/COMBINATION VACCINES BY REGION, 2014-2021 ($ MILLIONS) 85
FIGURE 12 GLOBAL SALES OF ANIMAL HEALTH PRODUCTS BY MARKET LEADER, 2014-2016 ($ MILLIONS) 89
FIGURE 13 GLOBAL MARKET FOR ANIMAL VACCINES BY TYPE, 2014-2021 ($ MILLIONS) 92
FIGURE 14 GLOBAL MARKET FOR VACCINES FOR FOOD-PRODUCING ANIMALS BY REGION, 2014-2021 ($ MILLIONS) 97
FIGURE 15 GLOBAL MARKET FOR VACCINES FOR COMPANION ANIMALS BY REGION, 2014-2021 ($ MILLIONS) 99
FIGURE 16 GLOBAL MARKET FOR OTHER ANIMAL VACCINES BY REGION, 2014-2021 ($ MILLIONS) 101
FIGURE 17 GLOBAL MARKET SHARES OF SALES OF ANIMAL VACCINES BY TYPE, 2015 (%) 102
FIGURE 18 GLOBAL SALES OF ANIMAL VACCINES BY REGION, THROUGH 2021 ($ MILLIONS) 104
FIGURE 19 GLOBAL MARKET SHARES OF ANIMAL VACCINE SALES BY REGION, 2015 (%) 105
FIGURE 20 GLOBAL MARKET SHARE OF MANUFACTURERS OF HUMAN VACCINE, 2015 (%) 114
FIGURE 21 ANIMAL VACCINE MANUFACTURERS GLOBAL MARKET SHARE, 2015 (%) 118
FIGURE 22 GLOBAL SALES OF HUMAN VACCINES FOR MENINGOCOCCAL/ PNEUMOCOCCAL DISEASES, 2014-2021 ($ MILLIONS) 124
FIGURE 23 GLOBAL MARKET SHARES OF TOP-SELLING MENINGOCOCCAL/ PNEUMOCOCCAL VACCINES, 2015 (%) 125
FIGURE 24 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET, 2014-2021 ($ MILLIONS) 127
FIGURE 25 GLOBAL MARKET SHARES OF TOP-SELLING INFLUENZA VACCINES, 2015 (%) 128
FIGURE 26 GLOBAL MARKET FOR HUMAN VACCINES PEDIATRIC POLIO/PERTUSSIS/HIB DISEASES MARKET, 2014-2021 ($ MILLIONS) 131
FIGURE 27 GLOBAL MARKET SHARES OF TOP-SELLING PEDIATRIC POLIO/PERTUSSIS/HIB VACCINES, 2015 (%) 132
FIGURE 28 GLOBAL MARKET FOR HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER DISEASES, 2014-2021 ($ MILLIONS) 134
FIGURE 29 GLOBAL MARKET SHARES OF TOP-SELLING ADULT/ADOLESCENT BOOSTER VACCINES, 2015 (%) 134
FIGURE 30 GLOBAL MARKET FOR HUMAN VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, 2014-2021 ($ MILLIONS) 137
FIGURE 31 GLOBAL MARKET SHARES OF TOP-SELLING VACCINES FOR TRAVEL-RELATED AND OTHER ENDEMIC DISEASES, 2015 (%) 138
FIGURE 32 GLOBAL MARKET FOR HUMAN VACCINES IN HPV, 2014-2021 ($ MILLIONS) 140
FIGURE 33 GLOBAL MARKET SHARES OF TOP-SELLING HPV VACCINES, 2015 (%) 141
FIGURE 34 GLOBAL MARKET FOR HUMAN VACCINES IN ROTAVIRUS, 2014-2021 ($ MILLIONS) 143
FIGURE 35 GLOBAL MARKET SHARES OF TOP-SELLING ROTAVIRUS VACCINES, 2015 (%) 144
FIGURE 36 GLOBAL MARKET FOR HUMAN VACCINES IN THE OTHER DISEASES SEGMENT, 2014-2021 ($ MILLIONS) 146
FIGURE 37 GLOBAL MARKET SHARES OF TOP-SELLING VACCINES IN THE OTHER DISEASES SEGMENT, 2015 (%) 147
FIGURE 38 GLOBAL MARKET SHARES OF HUMAN VACCINE SALES BY APPLICATION, 2015 (%) 149
FIGURE 39 U.S. PATENTS ISSUED FOR VACCINES BY YEAR, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS) 152
FIGURE 40 U.S. PATENTS BY TYPE OF VACCINES, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS) 153
FIGURE 41 PATENT SHARES BY PATENT HOLDER'S COUNTRY, JANUARY 2014-SEPTEMBER 2016 (%) 155
FIGURE 42 U.S. PATENTS BY ASSIGNEE TYPE, JANUARY 2014-SEPTEMBER 2016 (NUMBER OF PATENTS) 157

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

  • $ 59500
  • Industry report
  • January 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...


Download Unlimited Documents from Trusted Public Sources

Cardiovascular Disease Industry in Asia

  • February 2017
    2 pages
  • Cardiovascular ...  

  • Asia  

    United States  

View report >

Endocrine Disease Statistics in the US

  • February 2017
    115 pages
  • Endocrine Disea...  

    Diabetes Monito...  

    Hospital  

  • United States  

    North America  

View report >

Tuberculosis Statistics in the UK

  • February 2017
    10 pages
  • Tuberculosis  

  • United Kingdom  

    Europe  

View report >

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.